Spots Global Cancer Trial Database for metronomic chemotherapy
Every month we try and update this database with for metronomic chemotherapy cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of Oral Navelbine in Female Patients With HER2-Negative Metastatic Breast Cancer | NCT03854617 | Human Epidermal... | Oral NVB Metron... Oral NVB Weekly | 18 Years - 85 Years | ChineseAMS | |
| Metronomic Chemotherapy in Elderly Non-fit Patients With Aggressive B-Cell Lymphomas | NCT03161054 | Aggressive Non-... | Prednisone Vinorelbine Etoposide Cyclophosphamid... Rituximab | 65 Years - | Fondazione Italiana Linfomi - ETS | |
| A Study of the Addition of Metronomic Capecitabine to Standard Adjuvant Therapy in High Risk HER2+ BC paTients | NCT03561740 | Breast Cancer | capecitabine | 18 Years - 70 Years | Sun Yat-sen University | |
| Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer | NCT06229067 | Breast Cancer Triple Negative... | Adebrelimab Vinorelbine Cyclophosphamid... Capecitabine | 18 Years - | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| Efficacy Study of Revlimid® and Low Dose Continuously Administered Melphalan to Treat High Risk MDS | NCT00744536 | Myelodysplastic... Leukemia, Myelo... Angiogenesis | Lenalidomide an... | 18 Years - | Sunnybrook Health Sciences Centre | |
| Maintenance Metronomic Chemotherapy for Metastatic Colorectal Carcinoma | NCT01668680 | Colorectal Canc... | CAPECITABINE, C... | 18 Years - 80 Years | HaEmek Medical Center, Israel | |
| Oral Navelbine and Cisplatin Followed by Metronomic Oral Navelbine in Non-Small Cell Lung Cancer | NCT02985203 | Lung Neoplasm M... | Vinorelbine Ora... | 18 Years - | Guangdong Association of Clinical Trials | |
| Metronomic Treatment With Daily Oral Vinorelbine as First-line Chemotherapy in Patients With Advanced/Metastatic Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Breast Cancer | NCT03007992 | Metastatic Brea... | Vinorelbine | 18 Years - | Johannes Gutenberg University Mainz | |
| ZD6474 (Zactima) and Metronomic Chemotherapy in Advanced Breast Cancer | NCT00496665 | Metastatic Brea... | Vandetanib Cyclophosphamid... Methotrexate | 18 Years - | Dana-Farber Cancer Institute | |
| BP-C1 in Metastatic Breast Cancer Patients | NCT01861509 | Metastatic Brea... Stage IV Breast... | BP-C1 | 18 Years - 80 Years | Meabco A/S | |
| BP-C1 Monotherapy in Patients With Metastatic Breast Cancer Cancer: Estimation of Optimal Duration of Treatment | NCT03789019 | Metastatic Brea... Stage IV Breast... | BP-C1 | 18 Years - 80 Years | Meabco A/S | |
| Maintenance Treatment Versus Observation After Induction in Advanced Colorectal Carcinoma | NCT00442637 | Colorectal Canc... | capecitabine + ... observation | 18 Years - | Dutch Colorectal Cancer Group | |
| Capecitabine Maintenance Therapy Following Capecitabine Combined With Docetaxel in Treatment of mBC | NCT01917279 | Breast Neoplasm... Neoplasms by Si... Neoplasm Metast... Breast Diseases Skin Diseases | Docetaxel plus ... Intermittent Ca... Metronomic Cape... | 18 Years - | ChineseAMS | |
| BP-C1 in Short-term Treatment of Patients With Metastatic Breast Cancer | NCT02783794 | Metastatic Brea... Stage IV Breast... | BP-C1 Placebo | 18 Years - 80 Years | Meabco A/S | |
| BP-C1 in Short-term Treatment of Metastatic Pancreatic Cancer | NCT03627390 | Metastatic Panc... Unresectable Pa... | BP-C1 BP-C2 | 18 Years - 80 Years | Meabco A/S | |
| Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer | NCT06229067 | Breast Cancer Triple Negative... | Adebrelimab Vinorelbine Cyclophosphamid... Capecitabine | 18 Years - | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| Metronomic Chemotherapy in a Real-world Population of Advanced Breast Cancer Patients | NCT06373744 | Breast Cancer | cyclophosphamid... | 18 Years - | Sun Yat-sen University | |
| Metronomic Cyclophosphamide in Combination With Standard Chemotherapy for Squamous Cell Lung Carcinoma | NCT01947062 | Lung Cancer Squamous Cell C... Locally Advance... | Intravenous Cis... Intravenous Cis... | 18 Years - 75 Years | Swami Rama Cancer Hospital and Research Institute | |
| Bevacizumab With or Without Cyclophosphamide and Methotrexate: A Pilot Study in Women With Operable Breast Cancer | NCT00121134 | Breast Cancer | Bevacizumab Cyclophosphamid... Methotrexate Capecitabine | 18 Years - | Dana-Farber Cancer Institute | |
| Metronomic Chemotherapy in Wilms Tumor (MetroWilms-1906) | NCT05384821 | Wilms Tumor | Vincristine Irinotecan Temozolomide Etoposide Cis-Retinoic ac... | 18 Months - 17 Years | Centre Oscar Lambret | |
| A Study of the Addition of Metronomic Capecitabine to Standard Adjuvant Therapy in High Risk HER2+ BC paTients | NCT03561740 | Breast Cancer | capecitabine | 18 Years - 70 Years | Sun Yat-sen University | |
| Efficacy of Capecitabine Metronomic Chemotherapy to Triple-negative Breast Cancer | NCT01112826 | Breast Cancer | Capecitabine | 18 Years - 70 Years | Sun Yat-sen University | |
| Dose-finding Study of BP-C1 in Patients With Stage IV Breast Cancer | NCT04298333 | Metastatic Brea... Stage IV Breast... | BP-C1 | 18 Years - 80 Years | Meabco A/S | |
| Low-Dose/Metronomic(LDM)Chemotherapy for Metastatic Breast Cancer | NCT01067989 | Chemotherapy Breast Cancer, ... | Cyclophosphamid... | 18 Years - 80 Years | HaEmek Medical Center, Israel | |
| Metronomic Chemotherapy in a Real-world Population of Advanced Breast Cancer Patients | NCT06373744 | Breast Cancer | cyclophosphamid... | 18 Years - | Sun Yat-sen University | |
| Oral Navelbine and Cisplatin Followed by Metronomic Oral Navelbine in Non-Small Cell Lung Cancer | NCT02985203 | Lung Neoplasm M... | Vinorelbine Ora... | 18 Years - | Guangdong Association of Clinical Trials | |
| Dose-finding Study of BP-C1 in Patients With Stage IV Breast Cancer | NCT04298333 | Metastatic Brea... Stage IV Breast... | BP-C1 | 18 Years - 80 Years | Meabco A/S | |
| Regorafenib in Combination With Metronomic Chemotherapies, and Low-dose Aspirin in Metastatic Colorectal Cancer | NCT04534218 | Colo-rectal Can... Metastatic Canc... | Regorafenib Cyclophosphamid... Capecitabine Aspirin | 18 Years - | Centre Hospitalier Universitaire de Besancon | |
| BP-C1 in Short-term Treatment of Metastatic Pancreatic Cancer | NCT03627390 | Metastatic Panc... Unresectable Pa... | BP-C1 BP-C2 | 18 Years - 80 Years | Meabco A/S | |
| the Role of Two Different Metronomic Chemotherapy Regimens in Locally Advanced or Metastatic Triple Negative Breast Cancer Patients (TNBC) as Maintenance Therapy After First Line Treatment | NCT03358004 | Triple Negative... | Vinorelbine Tar... Capecitabine 50... | 18 Years - | Mario Negri Institute for Pharmacological Research | |
| Phase II Trial With Metronomic, Capecitabine Plus Oral Vinorelbine for Metastatic Breast Cancer | NCT01941771 | Breast Cancer | Arm B Vinorelbi... Arm A Vinorelbi... | 18 Years - | University of Aarhus | |
| the Role of Two Different Metronomic Chemotherapy Regimens in Locally Advanced or Metastatic Triple Negative Breast Cancer Patients (TNBC) as Maintenance Therapy After First Line Treatment | NCT03358004 | Triple Negative... | Vinorelbine Tar... Capecitabine 50... | 18 Years - | Mario Negri Institute for Pharmacological Research | |
| Efficacy Study of Revlimid® and Low Dose Continuously Administered Melphalan to Treat High Risk MDS | NCT00744536 | Myelodysplastic... Leukemia, Myelo... Angiogenesis | Lenalidomide an... | 18 Years - | Sunnybrook Health Sciences Centre | |
| Metronomic Cyclophosphamide in Combination With Standard Chemotherapy for Squamous Cell Lung Carcinoma | NCT01947062 | Lung Cancer Squamous Cell C... Locally Advance... | Intravenous Cis... Intravenous Cis... | 18 Years - 75 Years | Swami Rama Cancer Hospital and Research Institute | |
| Low-Dose/Metronomic(LDM)Chemotherapy for Metastatic Breast Cancer | NCT01067989 | Chemotherapy Breast Cancer, ... | Cyclophosphamid... | 18 Years - 80 Years | HaEmek Medical Center, Israel | |
| Metronomic Capecitabine, Oxaliplatin and UGT1A1 Genotype-directed Irinotecan in Metastatic Pancreatic Cancer Patients | NCT05929885 | Metastatic Panc... | Low Dose OXIRI ... | 21 Years - 99 Years | National Cancer Centre, Singapore | |
| Capecitabine Metronomic Chemotherapy Plus Aromatase Inhibitor for Postmenopausal Hormone Receptor Positive Breast Cancer | NCT01924078 | Breast Cancer | Capecitabine aromatase Inhib... | 18 Years - | Fudan University | |
| Phase II Trial With Metronomic, Capecitabine Plus Oral Vinorelbine for Metastatic Breast Cancer | NCT01941771 | Breast Cancer | Arm B Vinorelbi... Arm A Vinorelbi... | 18 Years - | University of Aarhus | |
| BP-C1 in Short-term Treatment of Thai Patients With Metastatic Breast Cancer | NCT03603197 | Metastatic Brea... Stage IV Breast... | BP-C1 Placebo | 18 Years - 80 Years | Meabco A/S | |
| the Role of Two Different Metronomic Chemotherapy Regimens in Locally Advanced or Metastatic Triple Negative Breast Cancer Patients (TNBC) as Maintenance Therapy After First Line Treatment | NCT03358004 | Triple Negative... | Vinorelbine Tar... Capecitabine 50... | 18 Years - | Mario Negri Institute for Pharmacological Research | |
| Metronomic Treatment With Daily Oral Vinorelbine as First-line Chemotherapy in Patients With Advanced/Metastatic Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Breast Cancer | NCT03007992 | Metastatic Brea... | Vinorelbine | 18 Years - | Johannes Gutenberg University Mainz | |
| Maintenance Treatment Versus Observation After Induction in Advanced Colorectal Carcinoma | NCT00442637 | Colorectal Canc... | capecitabine + ... observation | 18 Years - | Dutch Colorectal Cancer Group |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
